26.11.2012 Views

Guidelines for ATC classification and DDD assignment - WHOCC

Guidelines for ATC classification and DDD assignment - WHOCC

Guidelines for ATC classification and DDD assignment - WHOCC

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Alterations in <strong>ATC</strong> <strong>classification</strong> are made when the main use of a drug has clearly<br />

changed, <strong>and</strong> when new groups are required to accommodate new substances or to<br />

achieve better specificity in the groupings.<br />

When it is decided to make an alteration, the following principles are used:<br />

- Space is provided <strong>for</strong> possible future extension of an <strong>ATC</strong> group.<br />

- The <strong>ATC</strong> code assigned to combination products should correspond as far as<br />

possible with the <strong>classification</strong> of the single substances in question.<br />

- Previous <strong>ATC</strong> codes <strong>for</strong> deleted products are not used <strong>for</strong> new substances.<br />

- Obsolete drugs or drugs withdrawn from the market are kept in the <strong>ATC</strong> system,<br />

since exclusion of substances from the <strong>ATC</strong> system may create difficulties <strong>for</strong><br />

the users of the system when considering historical data.<br />

- Changes of currently valid codes are kept to a minimum. A gap in the sequence<br />

is preferred to changing codes.<br />

When an <strong>ATC</strong> code is altered, the <strong>DDD</strong> is also reviewed. For example, when the<br />

<strong>classification</strong> of chloroquine was changed from <strong>ATC</strong> group M to P (i.e. classified<br />

only as an antimalarial), the <strong>DDD</strong> was changed since the dosages used <strong>for</strong><br />

treatment of malaria are different from the dosages used <strong>for</strong> rheumatic disorders.<br />

E. The EphMRA <strong>classification</strong> system<br />

The <strong>ATC</strong> <strong>classification</strong> system was originally based on the same main principles as<br />

the Anatomical Classification (AC-system) developed by the European<br />

Pharmaceutical Market Research Association (EphMRA) <strong>and</strong> the Pharmaceutical<br />

Business Intelligence <strong>and</strong> Research Group (PBIRG).In the EphMRA system, drugs<br />

are classified in groups at three or four different levels. The <strong>ATC</strong> <strong>classification</strong><br />

system is modified <strong>and</strong> extended from the EphMRA system by the addition of a<br />

therapeutic/pharmacological/chemical subgroup as the fourth level <strong>and</strong> a fifth level<br />

<strong>for</strong> the chemical substance.<br />

Since 1991 there has been a consultation between the EphMRA <strong>classification</strong><br />

committee <strong>and</strong> the WHO Collaborating Centre <strong>for</strong> Drug Statistics Methodology in<br />

order to achieve a better harmonisation between the two systems. The aim of this<br />

harmonisation process is to make the systems consistent down to the <strong>ATC</strong> 3rd<br />

level, where this is possible, <strong>and</strong> to describe the differences (i.e. show the<br />

differences by giving bridges) <strong>and</strong> similarities in groups where harmonisation is not<br />

21

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!